文献速递冠心病肺血管病与心包/心肌炎

利伐沙班联合阿司匹林治疗冠心病或外周动脉疾病患者的大出血分析

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本研究基于COMPASS试验,比较利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次与阿司匹林单药治疗冠心病或外周动脉疾病患者的大出血情况。结果显示联合治疗增加大出血风险(改良ISTH大出血HR 1.70),主要来自胃肠道,多发生于随机化后第一年且多为轻中度,常规支持治疗可管理。

要点

  • 联合治疗增加大出血风险(改良ISTH大出血HR 1.70;95%CI 1.40-2.05),以胃肠道最常见。
  • 多数超额出血发生在随机化后第一年,且约四分之三的大出血为轻中度。
  • 两组大出血患者接受血小板、凝血因子或其他止血治疗的比例相似。

核心结论

  • 与阿司匹林单药相比,利伐沙班联合阿司匹林增加大出血风险,主要来自胃肠道。
  • 多数超额出血发生在随机化后第一年,为轻中度,且经常规支持治疗可管理。

研究设计与样本

  • COMPASS研究的事后分析,纳入18,278例冠心病或外周动脉疾病患者,随机接受利伐沙班2.5mg每日两次联合阿司匹林100mg每日一次或阿司匹林单药,平均随访23个月。

主要发现

  • 联合治疗组改良ISTH大出血发生率为3.1%(288/9,152),阿司匹林组为1.9%(170/9,126),HR 1.70(95%CI 1.40-2.05),p<0.001。
  • 联合治疗组ISTH大出血发生率为2.3%(206/9,152),阿司匹林组为1.3%(116/9,126),HR 1.78(95%CI 1.41-2.23),p<0.0001。
  • 联合治疗组轻微出血发生率为9.2%(838/9,152),阿司匹林组为5.5%(503/9,126),HR 1.70(95%CI 1.52-1.90),p<0.0001。
  • 联合治疗组需要红细胞输注的比例为1.0%(87/9,152),阿司匹林组为0.5%(44/9,126),HR 1.97(95%CI 1.37-2.83),p=0.0002。
  • 胃肠道是大出血增加最常见的部位(联合组1.5% vs 阿司匹林组0.7%),HR 2.15(95%CI 1.60-2.89),p<0.001;约三分之一为胃或十二指肠出血,三分之一为结肠或直肠出血,三分之一为未知胃肠道部位出血。

临床怎么用

  • 对于冠心病或外周动脉疾病患者,采用利伐沙班联合阿司匹林治疗时应警惕大出血风险,尤其是胃肠道出血。
  • 联合治疗后的出血多发生在治疗第一年,且多为轻中度,常规支持治疗通常有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding. OBJECTIVES: This study sought to explore the effects of the combination of rivaroxaban and aspirin compared with aspirin on sites, timing, severity, and management of bleeding in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) study. METHODS: This study reports, by treatment group, the number and proportion of patients; hazard rate ratios for bleeding according to site and severity; the timing of bleeding using landmark analyses; and the number and proportion of patients who received blood products and other hemostatic treatments. RESULTS: Of 27,395 patients enrolled (mean age 68 years, 22% women), 18,278 were randomized to the combination of rivaroxaban and aspirin or to aspirin alone and followed for a mean of 23 months. Compared with aspirin alone, the combination increased modified International Society on Thrombosis and Hemostasis major bleeding (288 of 9,152 [3.1%] vs. 170 of 9,126 [1.9%]), (HR: 1.70; 95% CI: 1.40 to 2.05; p < 0.001), International Society on Thrombosis and Hemostasis major bleeding (206 of 9,152 [2.3%] vs. 116 of 9,126 [1.3%]), (HR: 1.78; 95% CI: 1.41 to 2.23; p < 0.0001), and minor bleeding (838 of 9,152 [9.2%] vs. 503 of 9,126 [5.5%]), (HR: 1.70; 95% CI 1.52 to 1.90; p < 0.0001); the combination also increased the need for any red cell transfusion (87 of 9,152 [1.0%] vs. 44 of 9,126 [0.5%]), (HR: 1.97; 95% CI 1.37 to 2.83, p = 0.0002). The gastrointestinal (GI) tract was the most common site of increased major bleeding (140 of 9,152 [1.5%] vs. 65 of 9,126 [0.7%]), (HR: 2.15; 95% CI: 1.60 to 2.89; p < 0.001), and the increase in bleeding was predominantly in the first year after randomization. Approximately one-third of major GI bleeding was gastric or duodenal, one-third was colonic or rectal, and one-third was from an unknown GI site. The study investigators reported that approximately three-quarters of major bleeding episodes were of mild or moderate intensity. A similar proportion of patients in each treatment group who experienced major bleeding received platelets, clotting factors, or other hemostatic agents. CONCLUSIONS: The combination of rivaroxaban and aspirin compared with aspirin alone increased major bleeding, mainly from the GI tract. Most excess bleeding occurred during the first year after randomization, was of mild or moderate intensity, and was managed with conventional supportive therapy. (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Eikelboom JW, Bosch JJ, Connolly SJ, et al. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. J Am Coll Cardiol. 2019. PMID: 31537259. doi:10.1016/j.jacc.2019.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。